Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

2.449 +0.029 (+1.21%)
Streaming Delayed Price Updated: 1:29 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 63,590,693
Open 3.400
Bid (Size) 2.440 (1,500)
Ask (Size) 2.450 (1,200)
Prev. Close 2.420
Today's Range 2.420 - 3.535
52wk Range 0.6600 - 2.999
Shares Outstanding 60,705,391
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today?
Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials. 
Via Benzinga
Gapping stocks in Monday's session
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill

Performance

YTD
+45.8%
+45.8%
1 Month
+7.9%
+7.9%
3 Month
+16.6%
+16.6%
6 Month
+185.2%
+185.2%
1 Year
+4.7%
+4.7%

More News

Read More
Discover the top movers in Monday's pre-market session.
Via Chartmill
Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments
Via Stocktwits
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
From Caribou Biosciences, Inc.
Via GlobeNewswire
Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
Via MarketMinute
Topics Artificial Intelligence Climate Change Economy
Caribou Biosciences Inc (NASDAQ:CRBU) Posts Mixed Q2 2025 Earnings with Revenue Beat but Wider Loss
Via Chartmill
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
Via Benzinga
Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
CRBU DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important February 24 Deadline in Securities Class Action - CRBU
From The Rosen Law Firm PA
Via GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
From Faruqi & Faruqi LLP
Via GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire

Frequently Asked Questions

Is Caribou Biosciences, Inc. - Common Stock publicly traded?
Yes, Caribou Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Caribou Biosciences, Inc. - Common Stock trade on?
Caribou Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Caribou Biosciences, Inc. - Common Stock?
The ticker symbol for Caribou Biosciences, Inc. - Common Stock is CRBU on the Nasdaq Stock Market
What is the current price of Caribou Biosciences, Inc. - Common Stock?
The current price of Caribou Biosciences, Inc. - Common Stock is 2.449
When was Caribou Biosciences, Inc. - Common Stock last traded?
The last trade of Caribou Biosciences, Inc. - Common Stock was at 11/03/25 01:29 PM ET
What is the market capitalization of Caribou Biosciences, Inc. - Common Stock?
The market capitalization of Caribou Biosciences, Inc. - Common Stock is 148.68M
How many shares of Caribou Biosciences, Inc. - Common Stock are outstanding?
Caribou Biosciences, Inc. - Common Stock has 149M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.